In a world dominated by billion-dollar biotech giants, Data2Bio is a quiet anomaly. With just 5 employees and $0.8M in revenue, they aren't playing the VC funding game—they're building a sustainable niche in the high-stakes world of genomic selection.

"In biotech, scale usually requires capital. Data2Bio proves that precision requires talent."

The biotech industry often conflates funding with viability. Data2Bio challenges this narrative. Operating out of the US with a lean team, they utilize a modern web stack (Tailwind, DaisyUI) to keep overhead low. Their revenue of $0.8M per employee is a testament to high-value service delivery rather than mass-market volume.

• Proprietary IP: tGBS® technology is a defensible moat against generic sequencing services.
• Lean Operations: 5 employees generating $0.8M revenue implies high efficiency.
• Niche Dominance: Targets breeders specifically, avoiding the crowded consumer genomics space.